Plasma Membrane Vesicles for NK Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding natural killer (NK) cells are limited by the need for live feeder cells, which complicates clinical applications, and existing cytokine-based expansion methods often result in toxicity and short persistence of NK cells.
Innovation Solution
The use of plasma membrane vesicles and membrane self-inserting peptide conjugates containing NK cell effector agents such as IL-15, IL-21, and 41BBL to stimulate and expand NK cells in vitro and in vivo, eliminating the need for live feeder cells and potentially reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If live feeder cells are used to expand NK cells, then NK cell expansion is achieved, but device complexity and ease of operation deteriorate due to the need for complex cell culture systems
Solution Approach 1:
The patent extracts the essential function of live feeder cells (providing cytokines and cell-to-cell contact signals) and isolates it into purified plasma membrane vesicles containing NK cell effector agents. This extraction eliminates the complexity of maintaining live cell cultures while preserving the NK cell expansion capability.
Solution Approach 2:
The patent creates artificial copies of the feeder cell membrane surface by generating plasma membrane vesicles that replicate the essential membrane-bound cytokines and ligands. These vesicle copies provide the necessary stimulation signals without requiring the complex biological system of live feeder cells.
2Quantity of substance
If traditional cytokine-based methods are used to expand NK cells, then NK cell numbers increase, but reliability deteriorates due to toxicity and short persistence
Solution Approach 1:
The patent applies local quality by delivering cytokines in a localized, controlled manner through plasma membrane vesicles. The effector agents are presented on the vesicle surface in specific spatial arrangements that mimic natural cell membranes, providing localized stimulation that reduces systemic toxicity while maintaining effective NK cell activation and persistence.
Solution Approach 2:
The patent uses composite materials by combining plasma membrane vesicles containing multiple NK cell effector agents (such as IL-15, IL-21, and 41BBL) with targeted delivery systems. This composite approach allows coordinated presentation of multiple cytokines and ligands, enhancing NK cell persistence and reducing the need for high doses of individual cytokines, thereby improving safety.
3Productivity
If high doses of cytokines are administered to achieve therapeutic NK cell doses, then productivity improves, but object-affected harmful factors worsen due to cytokine toxicity
Solution Approach 1:
The patent introduces plasma membrane vesicles as intermediaries between the cytokine effector agents and the NK cells. These vesicles serve as controlled delivery vehicles that present cytokines in a regulated manner, enabling effective NK cell expansion at lower overall cytokine doses and reducing systemic toxicity associated with high-dose cytokine administration.
Data Source
AI summary
The application provides new compositions and methods for stimulating the production of natural killer (NK) cells in a subject. NK cells can be selectively expanded with a combination of stimulating ligands. Methods and compositions for the administration of stimulatory ligands modified to self-insert into tumor cells, thereby stimulating an increase in the number of NK cells in proximity to a tumor, are also described.